|
Targeting B-cell lymphoma with Leukothera
|
1R41CA173900-01
|
$202,601
|
$202,601
|
Belinka, Benjamin
|
ACTINOBAC BIOMED, INC.
|
|
Detection of Light Chain Restriction in non-Hodgkin Lymphoma by a Novel RNA In Si
|
1R43CA168019-01
|
$268,010
|
$268,010
|
Ma, Xiao-Jun
|
ADVANCED CELL DIAGNOSTICS, INC.
|
|
Core Support for Cancer Center
|
3P30CA013330-39S4
|
$3,757,417
|
$150,297
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S5
|
$249,999
|
$10,000
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S6
|
$249,999
|
$10,000
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S7
|
$75,000
|
$3,000
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Somatic Mutation of IG Variable Regions
|
5R01CA072649-14
|
$394,809
|
$394,809
|
SCHARFF, MATTHEW
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Mismatch repair in V region mutation and isotype switching
|
5R01CA102705-09
|
$314,906
|
$314,906
|
SCHARFF, MATTHEW
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
5U10CA014958-38
|
$101,749
|
$1,017
|
Sparano, Joseph
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
CD20-targeted IL-15 immunotherapeutic for B-cell malignancies
|
1R43CA174091-01
|
$257,303
|
$128,652
|
WONG, HING
|
ALTOR BIOSCIENCE CORPORATION
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-23
|
$486,165
|
$4,862
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
Hamster Model of SV40 Infection and Disease
|
5R01CA134524-04
|
$308,959
|
$308,959
|
BUTEL, JANET
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
2P50CA126752-06
|
$2,300,000
|
$644,000
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-06S1
|
$41,433
|
$1,243
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-06S2
|
$75,000
|
$2,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-06
|
$2,934,758
|
$88,043
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mechanism and Consequences of Telomere Dysfunction
|
5R01CA133249-05
|
$308,957
|
$154,479
|
Songyang, Zhou
|
BAYLOR COLLEGE OF MEDICINE
|
|
Engineered tumor-specific T cells Resist Hypoxic-Tumor Immunosuppressive Attacks.
|
5R01CA142664-03
|
$308,958
|
$308,958
|
YOTNDA, PATRICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-14
|
$95,411
|
$954
|
BUBLEY, GLENN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Dual role of IL-16 in dysregulated growth of CTCL cells
|
5R01CA122737-04
|
$326,469
|
$326,469
|
Cruikshank, William
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Cancer and Leukemia Group B
|
3U10CA031946-31S1
|
$114,228
|
$5,711
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-27S1
|
$405,901
|
$8,118
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B
|
5U10CA031946-31
|
$7,759,618
|
$387,981
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B CCOP Research Base
|
5U10CA037447-28
|
$2,286,202
|
$45,724
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
A prospective analysis of peripheral blood cytokines and non-Hodgkin lymphoma
|
5R01CA149445-02
|
$549,324
|
$549,324
|
BIRMANN, BRENDA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Genetic and Proteomic Analysis of Epstein-Barr Virus LMP1 Activation of NF-kB
|
5K08CA140780-03
|
$179,910
|
$89,955
|
Gewurz, Benjamin
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus Nuclear Protein in B Cell Growth Transformation
|
2R01CA047006-25
|
$565,231
|
$282,616
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus LMP1-Mediated Oncogenecity
|
2R01CA085180-11A1
|
$701,405
|
$350,703
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Inhibitors of Epstein-Barr Virus Nuclear Protein 1 Mediated Latent Infection
|
5R01CA131354-04
|
$359,276
|
$359,276
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
SPORE in Skin Cancer
|
5P50CA093683-10
|
$2,300,000
|
$345,000
|
KUPPER, THOMAS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
The role of miR-155 in cell cycle regulation and tumorigenesis
|
5F32CA139883-03
|
$53,942
|
$53,942
|
So, Alex
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-38
|
$354,850
|
$3,549
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Bcl-2 function on the endoplasmic reticulum
|
5R01CA085804-13
|
$284,448
|
$113,779
|
DISTELHORST, CLARK
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
|
5U01CA062502-19
|
$594,035
|
$5,940
|
DOWLATI, AFSHIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-22S3
|
$4,849,180
|
$48,492
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-22S4
|
$74,396
|
$744
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Exploiting synthetic lethality of hematopoietic lineage cells to develop novel ta
|
5R44CA141848-03
|
$905,570
|
$452,785
|
Bonneau, Kyle
|
CELLECTA, INC.
|
|
RhoH GTPase in Hematopoiesis and Cancer
|
5R01CA113969-08
|
$325,549
|
$81,387
|
WILLIAMS, DAVID
|
CHILDREN'S HOSPITAL BOSTON
|
|
Research and Mentoring on Energetic Factors and Cancer: Established Investigator
|
5K05CA136967-04
|
$137,885
|
$6,894
|
BERNSTEIN, LESLIE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
City of Hope Lymphoma SPORE
|
5P50CA107399-07
|
$2,300,000
|
$1,472,000
|
Forman, Stephen
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-29S1
|
$91,911
|
$4,596
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-29S2
|
$139,999
|
$7,000
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-29S3
|
$75,000
|
$3,750
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
5P30CA033572-29
|
$2,225,352
|
$111,268
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Phase I Molecular and Clincal Pharmacodynamic Trials
|
5U01CA062505-19
|
$592,432
|
$35,546
|
NEWMAN, EDWARD
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Molecular epidemiology of non-Hodgkin lymphoma prognosis and prevention
|
1R01CA166219-01
|
$716,410
|
$716,410
|
Wang, Sophia
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Evaluating New Targets of CMV Cellular Immunity
|
5R01CA145207-07
|
$393,139
|
$196,570
|
Zaia, John
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cold Spring Harbor Laboratory Cancer Research Center
|
2P01CA013106-41
|
$4,298,042
|
$128,941
|
HANNON, GREGORY
|
COLD SPRING HARBOR LABORATORY
|
|
Cold Spring Harbor Laboratory Cancer Research Center
|
3P01CA013106-41S1
|
$188,000
|
$5,640
|
Hannon, Gregory
|
COLD SPRING HARBOR LABORATORY
|
|
CSHL CANCER CENTER SUPPORT GRANT
|
5P30CA045508-25
|
$4,346,720
|
$43,467
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
Total relevant funding to Non Hodgkins Lymphoma for this search: $119,470,587
|